• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    12/26/23 12:31:10 PM ET
    $BACK
    $BCEL
    $GRCL
    $KNW
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BACK alert in real time by email

    Gainers

    • RayzeBio (NASDAQ:RYZB) stock moved upwards by 100.8% to $61.4 during Tuesday's regular session. The market value of their outstanding shares is at $3.6 billion.
    • IMAC Hldgs (NASDAQ:BACK) stock moved upwards by 74.02% to $4.21. The company's market cap stands at $4.7 million.
    • Gracell Biotechnologies (NASDAQ:GRCL) shares increased by 59.93% to $9.9. The company's market cap stands at $949.6 million.
    • Sight Sciences (NASDAQ:SGHT) stock rose 44.61% to $5.26. The market value of their outstanding shares is at $256.6 million.
    • 60 Degrees (NASDAQ:SXTP) shares moved upwards by 44.17% to $1.3. The market value of their outstanding shares is at $7.5 million.
    • Science 37 Hldgs (NASDAQ:SNCE) stock increased by 43.47% to $6.23. The market value of their outstanding shares is at $37.1 million.

    Losers

    • Milestone Pharmaceuticals (NASDAQ:MIST) shares decreased by 32.3% to $1.95 during Tuesday's regular session. The market value of their outstanding shares is at $65.2 million.
    • ENDRA Life Sciences (NASDAQ:NDRA) stock decreased by 22.01% to $1.95. The market value of their outstanding shares is at $16.4 million.
    • Jin Medical International (NASDAQ:ZJYL) stock decreased by 18.51% to $111.67. The company's market cap stands at $865.4 million.
    • Know Labs (AMEX:KNW) shares decreased by 18.15% to $0.48. The market value of their outstanding shares is at $38.7 million.
    • YS Biopharma Co (NASDAQ:YS) stock decreased by 16.78% to $0.47. The company's market cap stands at $43.7 million.
    • Atreca (NASDAQ:BCEL) stock fell 15.91% to $0.19. The market value of their outstanding shares is at $7.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BACK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BACK
    $BCEL
    $GRCL
    $KNW

    CompanyDatePrice TargetRatingAnalyst
    Sight Sciences Inc.
    $SGHT
    1/5/2026$9.00Neutral → Overweight
    Piper Sandler
    Milestone Pharmaceuticals Inc.
    $MIST
    12/15/2025$8.00Hold → Buy
    TD Cowen
    Milestone Pharmaceuticals Inc.
    $MIST
    9/11/2025$4.00Overweight
    Wells Fargo
    Sight Sciences Inc.
    $SGHT
    8/8/2025$5.00Hold → Buy
    Lake Street
    Milestone Pharmaceuticals Inc.
    $MIST
    6/5/2025$5.00Buy
    H.C. Wainwright
    Sight Sciences Inc.
    $SGHT
    12/6/2024$5.50Buy
    UBS
    Sight Sciences Inc.
    $SGHT
    11/4/2024$10.00 → $5.00Buy → Hold
    Lake Street
    Milestone Pharmaceuticals Inc.
    $MIST
    8/22/2024$9.00Buy
    Rodman & Renshaw
    More analyst ratings

    $BACK
    $BCEL
    $GRCL
    $KNW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Tokman Alexander Y was granted 26,921 shares, increasing direct ownership by 36% to 101,926 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:18 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Jacroux Richard was granted 13,461 shares, increasing direct ownership by 67% to 33,461 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:01 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Technology Officer Badawi David exercised 21,270 shares at a strike of $0.23, increasing direct ownership by 1% to 1,998,458 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    2/23/26 4:28:55 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $BACK
    $BCEL
    $GRCL
    $KNW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Encrantz Staffan bought $115,963 worth of shares (13,958 units at $8.31), increasing direct ownership by 1% to 1,391,922 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    12/18/25 6:10:08 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    President and CEO Dow Geoffrey S bought $7,759 worth of shares (9,670 units at $0.80), increasing direct ownership by 19% to 59,618 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/16/25 5:41:35 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Dow Geoffrey S bought $12,204 worth of shares (12,963 units at $0.94), increasing direct ownership by 35% to 49,948 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/12/25 8:39:45 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BACK
    $BCEL
    $GRCL
    $KNW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

    MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced that it will report fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026, before the market opens. The announcement will be followed by a conference call and webcast for investors at 8:30am ET. Conference Details: Conference Dial-in:1-877-407-0792International Dial-in:1-201-689-8263Conference ID:13759195Webcast link:click here Call me™: Participants can use Guest dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. The Call me™ link will be made acti

    3/12/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jin Medical International Ltd. Announces 1-for-20 Share Combination as Part of Strategic Nasdaq Compliance Initiative

    CHANGZHOU, China, March 11, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ:ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment, today announced that its Board of Directors has approved an 1-for-20 share combination of all its authorized and issued ordinary shares (the "Stock Combination") pursuant to the authorization granted from an extraordinary general meeting of the Company's shareholders on January 30, 2026 (the "EGM"). Effective as of the date of the EGM, the Company's authorized share capital is reclassified into a dual class of Class A ordinary shares

    3/11/26 7:30:00 PM ET
    $ZJYL
    Industrial Specialties
    Health Care

    60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

    All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publicationCompany calls for existing babesiosis treatment guidelines to be reviewed in light of the new data WASHINGTON, March 11, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three of three enrolled patients have been cured of babesiosis after completing the tafenoquine regimen in the Company's trial of relapsing babesiosis in immunosuppressed patients. The Com

    3/11/26 7:24:00 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BACK
    $BCEL
    $GRCL
    $KNW
    SEC Filings

    View All

    SEC Form 424B5 filed by 60 Degrees Pharmaceuticals Inc.

    424B5 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    3/13/26 5:17:36 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    60 Degrees Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    3/13/26 5:15:16 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    60 Degrees Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    3/12/26 4:36:53 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BACK
    $BCEL
    $GRCL
    $KNW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sight Sciences upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sight Sciences from Neutral to Overweight and set a new price target of $9.00

    1/5/26 8:36:47 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Milestone Pharmaceuticals upgraded by TD Cowen with a new price target

    TD Cowen upgraded Milestone Pharmaceuticals from Hold to Buy and set a new price target of $8.00

    12/15/25 10:09:22 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Milestone Pharmaceuticals with a new price target

    Wells Fargo initiated coverage of Milestone Pharmaceuticals with a rating of Overweight and set a new price target of $4.00

    9/11/25 8:45:07 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BACK
    $BCEL
    $GRCL
    $KNW
    Leadership Updates

    Live Leadership Updates

    View All

    Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

    MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval's appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025. He will serve as a member of Milestone's executive leadership team and will provide business-focused legal counsel across all

    2/10/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of Alison (Ali) Bauerlein as its Chief Operating Officer (COO) and James (Jim) Rodberg as its Chief Financial Officer (CFO), effective November 5, 2025. "We are very excited to promote both Ali and Jim into new roles at Sight Sciences as we continue to elevate our market leadership position in MIGS and begin to scale the reimbursed interventional dry eye category. We believe the many contribu

    11/6/25 4:04:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Appoints Gary Burbach to its Board of Directors

    MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very excited to add Gary to our Board of Directors," stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. "He brings a strong medtech industry background with a pro

    4/22/25 4:05:00 PM ET
    $BWXT
    $SGHT
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    $BACK
    $BCEL
    $GRCL
    $KNW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by 60 Degrees Pharmaceuticals Inc.

    SC 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

    11/14/24 3:37:18 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sight Sciences Inc.

    SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

    11/14/24 11:57:36 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by 60 Degrees Pharmaceuticals Inc.

    SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

    11/13/24 4:01:15 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BACK
    $BCEL
    $GRCL
    $KNW
    Financials

    Live finance-specific insights

    View All

    Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

    MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced that it will report fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026, before the market opens. The announcement will be followed by a conference call and webcast for investors at 8:30am ET. Conference Details: Conference Dial-in:1-877-407-0792International Dial-in:1-201-689-8263Conference ID:13759195Webcast link:click here Call me™: Participants can use Guest dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. The Call me™ link will be made acti

    3/12/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the fourth quarter and full year ended December 31, 2025 and initiated financial guidance for full year 2026.   Recent Financial Highlights Generated fourth quarter 2025 total revenue of $20.4 million, an increase of 7% compared to the same period in the prior year, and full year 2025 total revenue of $77.4 million, a decrease of 3% compared to full year 2

    3/4/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

    MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Wednesday, March 4, 2026. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast

    2/18/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care